Therapeutic effects of Zuojin Pill on Helicobacter pylori-induced chronic atrophic gastritis through JMJD2B/COX-2/VEGF signaling axis

Shihua Wu (✉ 1263588540@qq.com)  
Chengdu University of Traditional Chinese Medicine

Chunmei Bao  
The Fifth Medical Center of PLA General Hospital

Ruilin Wang  
The Fifth Medical Center of PLA General Hospital

Xiaomei Zhang  
Institute of Medica Chemistry of Chinese Medicine, Chongqing Academy of Chinese Materia Medica

Sijia Gao  
Institute of Medicinal Chemistry of Chinese Medicine, Chongqing Academy of Chinese Materia Medica

Weihan Qin  
Institute of Medicinal Chemistry of Chinese Medicine, Chongqing Academy of Chinese Materia Medica

Jianzhong Zhang  
National institute for communicable disease control and prevebtion

Juling Zhang  
The Fifth Medical Center of PLA General Hospital

Ruisheng Li  
The Fifth Medical Center of PLA General Hospital

Xing Chen  
Chengdu University of Traditional Chinese Medicine

Jianxia Wen  
Chengdu University of Traditional Chinese Medicine

Tao Yang  
Chengdu University of Traditional Chinese Medicine

Shizhang Wei  
Chengdu University of Traditional Chinese Medicine

Haotian Li  
The Fifth Center of PLA General Hospital

Ying Wei  
Chengdu University of Traditional Chinese Medicine

Sichen Ren
Research

Keywords: Zuojin Pill, Chronic atrophic gastritis, Helicobacter pylori, JMJD2B, Cyclooxygenase-2, vascular endothelial growth factor

Posted Date: June 11th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-20652/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Zuojin Pill (ZJP), a famous Chinese medicinal formula, widely accepted for treatment of chronic atrophic gastritis (CAG) in China. This study aimed to explore the therapeutic effects and mechanisms of ZJP in Helicobacter pylori (H. pylori) - induced chronic atrophic gastritis (CAG) in vivo and in vitro.

Methods: CAG rat model was induced by H. pylori. ZJP (0.63, 1.26, and 2.52 g/kg, respectively) was administered orally for four weeks. Therapeutic effects of ZJP were identified by H&E staining and serum indices. In addition, cell viability, morphology and proliferation were detected by cell counting kit-8 (CCK8) and high-content screening assay (HCS), respectively. Moreover, relative mRNA expression and protein expression related to JMJD2B/COX-2/VEGF axis was detected to investigate the potential mechanisms of ZJP in CAG. Results: Results showed the symptoms (weight loss and gastric mucosa damage) of CAG were alleviated, and the contents of TNF-α in serum was markedly decreased after treating with ZJP. Moreover, cell viability, proliferation and morphology changes of GES-1 cells were ameliorated by ZJP intervention. In addition, proinflammatory genes and JMJD2B/COX-2/VEGF axis related genes were suppressed by ZJP administration in vitro and in vivo. Meanwhile, immunohistochemistry (IHC) and western blot confirmed down-regulation of these genes by ZJP intervention.

Conclusion: ZJP treatment can alleviate gastric mucosal damage induced by H. pylori via JMJD2B/COX-2/VEGF axis.

Background

Chronic atrophic gastritis (CAG) is a universal disease in digestive system and one of the most continuous health concerns worldwide. Helicobacter pylori (H. pylori) infection is the strongest risk factor for gastric carcinogenesis [1]. H. pylori infection can induce CAG, which develops through the premalignant periods of intestinal metaplasia, and dysplasia, before eventually leading to gastric cancer [2]. At present, there are traditional options against H. pylori, including conventional triple therapy, bismuth based quadruple therapy and proton pump inhibitors [3]. Whether it is triple therapy, quadruple therapy or proton pump inhibitors, conventional therapies can cause a series of serious adverse reactions, such as abdominal pain, constipation, decline of eradication rates. Therefore, novel and safe drugs are badly needed to be discovered and used in clinical treatment as soon as possible. Copious evidences from China declare traditional Chinese medicine (TCM) possess unlimited potential in treating H. pylori induced CAG. As an alternative therapy, TCM are gaining increasing popularity worldwide for the clinical treatment [4]. Zuojin pill, recorded in the Danxi's experiential therapy, has been used for the treatment of gastrointestinal diseases for more than 700 years. However, the mechanism underlying the effect of ZJP in the treatment of H. pylori-induced CAG remains unclear.

ZJP contains Coptidis Rhizoma (CR) and Euodiae Fructus (EF) in the ratio of 6: 1 (w/w), which was initially recorded in an ancient medicine treatise, during China’s Yuan Dynasty for treating gastro-
intestinal disorders. CR is the dried rhizome of *Coptis chinensis Franch.*, *Coptisdeltoidea* C.Y. Cheng et Hsiao, or *Coptis teeta* Wall. (Chinese Pharmacopoeia Commission 2015). In clinical, it is often utilized to treat diarrhea, abdominal fullness, vomiting, jaundice, toothache, high fever coma, diabetes and eczema [5]. EF is the dried and immature fruit of *Euodia rutaecarpa (Juss.) Bentham.*, *Euodia rutaecarpa (Juss.) Bentham. var. officinalis* (Dode) Huang or *Euodia rutaecarpa (Juss.) Bentham. var. bodinieri* (Dode) Huang (Chinese Pharmacopoeia Commission 2015). EF is widely applied for the treatment of inflammation, headache, and hypertension [6]. Alkaloids are proved to be the primary compounds of CR and EF, including berberine, coptisine, palmatine, evodiamine and rutaecarpine. ZJP was officially listed in the Chinese Pharmacopoeia (2015 edition) as a common prescription employed in clinical patients, who suffer from esophagitis, gastritis, peptic ulcer, and other disorders. In traditional Chinese formula, ZJP is often used for the treatment of CAG [7]. In addition, ZJP and its active ingredients have obvious therapeutic effects against both inflammation and gastric mucosal damage in the stomach [8-9]. Recent study has exhibited the gastrointestinal regulating functions of ZJP by restoring gastric electrical rhythm [10]. Up to now, ZJP has been well-practiced in clinical application. The mechanism of ZJP acting on CAG is still unclear. In this study, we aimed to elucidate the effects and the molecular mechanisms of ZJP in *H. pylori*-induced CAG.

It has been reported that histone demethylase JMJD2B in stomach tissues when *H. pylori* infection became increased expression, and Cyclooxygenase-2 (COX-2) upregulated as downstream target protein of JMJD2B in *H. pylori* induced inflammatory process [11]. Histone modification is an epigenetic mechanism, which plays a crucial role in gastric cancer carcinogenesis [12]. JMJD2B was newly confirmed and characterized as a member of the histone demethylase JMJD2 family. Overexpress of JMJD2B is in gastric cancer can accelerate cell proliferation, survival, invasion and metastasis of gastric tumor [13]. *H. pylori* infection activates the JMJD2B promoter and upregulates expression at transcriptional level. Recently, evidence has shown that that JMJD2B is required for *H. pylori*-induced COX-2 activation. COX-2 is involved in inflammation as a key enzyme in the synthesis of prostaglandin and overexpresses after *H. pylori* infection [14]. The expression level of COX-2 is low under resting conditions in most cells, but can be induced by *H. pylori* in a cag T4SS-dependent manner [15]. In addition, JMJD2B was shown to regulate vascular endothelial growth factor (VEGF), phosphoinositide 3-kinase pathways, and angiogenesis, all of which play important roles in inflammation or tumorigenesis [16]. It is well known that in *H. pylori*-infected gastritis, the concentration of angiogenic factor increases, resulting in the formation of new blood vessels. New angiogenesis will enhance supplement of nutrient and oxygen, and thus promote the development of gastritis. COX-2 is the key target responsible for promoting angiogenesis, which stimulate Vascular endothelial growth factor (VEGF) expression induced by *H. pylori* [17].

In this study, we explored the curative effect of ZJP in *H. pylori* induced CAG *in vivo* and *in vitro*. Moreover, we attempted to conduct a preliminary examination of the roles of JMJD2B/COX-2/VEGF axis in mechanism of ZJP for better understanding protective effects of ZJP in CAG.
Methods

Material

Coptidis Rhizoma (Lot: 18011901) and Euodiae Fructus (Lot: 17021602) were purchased from Beijing Lvye Pharmaceutical Co., Ltd. (Beijing, China). The document codes of the product quality inspection number are CP-18-01-22 (Coptidis Rhizoma) and CP-17-02-11 (Euodiae Fructus). All detection results demonstrated that the quality of Coptidis Rhizoma and Euodiae Fructus was in complete requirement of in the Chinese Pharmacopoeia 2015. Omeprazole (positive drugs) was purchased from Astrazeneca Pharmaceutical Co., Ltd. (batch number: 1906194, Suzhou, China). All the other unspecified chemicals were of analytical grade.

Preparation of ZJP

Coptidis Rhizoma and Euodiae Fructus were soaked in pure water (6/1, w/w) for 30 min and were extracted twice (1 hour each time). Then, the extract was collected and evaporated to prepare dried powder under reduced pressure, respectively. Finally, the weight ratio of ZJP was 25.59%. ZJP powder was kept at 4°C until oral administration to rats. ZJP was dissolved in and acted on GES-1 cells. ZJP powder was dissolved in dimethyl sulfoxide (DMSO) to configure as mother liquor and then Dulbecco's modified Eagle's medium (DMEM) was used to dilute to corresponding concentration for using.

Bacterial strain and culture condition

*H. pylori* isolated strain (ICDC111001) was kindly provided by Dr. Jianzhong Zhang (Chinese Disease Control and Prevention Center, Beijing, China). *H. pylori* strain was maintained and grown on Columbia blood agar (Thermo Fisher Scientific, China), with incubation under micro-aerobic conditions (5% O₂, 10% CO₂, and 85% N₂) at 37°C. After three to five days’ culture, bacteria strain was collected and adjusted to 1.0×10⁸ colony forming units (CFU)/mL.

Animal experiments

Thirty-six male Sprague-Dawley (SD) rats were raised normally until 1 week before the experiments and maintained in the standard laboratory condition of stable temperature (25 ± 0.5°C), continuous humidity (55 ± 5%), alternant lighting (12 hours light: 12 hours dark cycle), and were free access to enough food and water. All specific pathogen free (SPF) male SD rats (170-190g) were purchased from Beijing Sibeifu Animal Breeding Center [Permission No. SCXK-(Jing) 2016–0002]. Firstly, the rats were randomly divided into the control group and model group. The rats in the model group were induced with *H. pylori* (1.5×10⁸ CFU/ml, 1.5 ml each rat) suspension to establish CAG model (4 times a week, at day 1, 3, 5 and 7) and rats in the control group were induced with equal volume saline by oral gavage. All rats were fasted about 12 h before intragastric administration. After 8 weeks, gastric tissues were obtained for rapid urease test
to detect the model. Finally, the CAG rats were randomly divided into five different groups with six rats in each, including the model group, ZJP low-dose (0.63 g/kg), medium-dose (1.26 g/kg) and high-dose (2.52 g/kg) groups, and Omeprazole group (1.8 mg/kg). All rats were administered once a day for 4 weeks. After 4 weeks, all rats were executed and gastric mucosa samples were isolated and cut in half along the greater curvature. The serum and half of the gastric tissue samples were collected and stored at -80°C to detect expression of gene and protein. The other of the gastric tissue samples were excised and fixed in 4% paraformaldehyde general tissue fixative, and then stained with H&E.

**Serum Tumor Necrosis Factor -α (TNF-α) and VEGF measurements**

The serum levels of TNF-α and VEGF were measured on a Synergy H1 Hybrid Reader (Biotech, USA). The measurement steps were conducted as per the manual of the ELISA kit (MLBIO biotechnology Co., Ltd., Shanghai, China).

**Immunohistochemistry (IHC)**

Paraffin-embedded rat stomach tissues were deparaffinized and antigen-repaired, and then samples with primary anti-JMJD2B Ab (Cat No.: ab191434, Abcam, 1:125) and anti-COX-2 Ab (Cat No.: 12375-1-AP, Proteintech, 1:100) incubated at 4°C for the night. Slides were then incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody and the slides were counterstained with hematoxylin. Light microscopy (Olympus, Japan) at 200× and 400× magnification was applied to photograph images.

**Cell viability assay and *H. pylori* infection**

The GES-1 cells were obtained from the FuHeng Cell Center, (Shanghai, China), which were cultivated in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a constant incubator containing 5% CO₂ at 37°C. The GES-1 cells were cultured overnight to reach at least 80% confluency. Cell viability was detected by cell counting kit-8 (CCK-8; Lot. PG658, DOJINDO, Japan). The optical density (OD) value was measured at 450 nm by using a Synergy H1 Hybrid Reader (Biotech, USA).

The *H. pylori* strain was harvested from Columbia blood agar plates, suspended in antibiotic-free DMEM medium complemented with 10% FBS, and then was added to the GES-1 cells culture. The *H. pylori* added to GES-1 cells at a multiplicity of infection (MOI) ratio of 10:1, 20:1, 50:1 and 100:1 for 0, 6, 12 and 24 h. Bacterial counting of *H. pylori* was examined through Synergy H1 Hybrid Reader (Biotech, USA). The measurement of OD value was set at 600 nm to count colony forming units of *H. pylori* (1 OD<sub>600nm</sub>=1.5×10<sup>8</sup> CFU/ml). Cocultivation was maintained at 37°C in a 5% CO₂ atmosphere.
High-Content Analysis Experiments (HCS)

Nuclear, cell morphology and the number of dead cells and living cells were detected by Array Scan High-Content System (Thermo Scientific, Massachusetts, USA) [18]. Hoechst 33342 (H3570, Invitrogen), calcein AM (C3099, Invitrogen), and ethidium homodimer-1 (EthD-1) (L3224, Invitrogen) were applied to quantify the GES-1 cells. Cell health profiling assay module was selected in the HCS system, and several different wavelength channels were set to collect fluorescence images. The measured parameters and format were similar to those used previously [19]. Array Scan XTI (The Array Scan software algorithm was used to perform analysis) was used to quantify the mean fluorescence intensity of GES-1 cells.

Real-time quantitative PCR Analysis in Vivo and in Vitro

Total mRNA of all rats’ gastric tissue and GES-1 cells were extracted by TRizol reagent (Nordic Bioscience, Beijing, China) and transformed into cDNA by reverse transcription kit (Promega, Madison, USA) according to the instructions. RT-qPCR for mRNA of JMJD2B, COX-2, VEGFR1, VEGFR2 and VEGF in rats and GES-1 cells were performed using SYBR Green PCR Master Mix (Nordic Bioscience, Beijing, China). Primer sequences are listed in Table 1. RT-qPCR was conducted on the 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA). Results were shown and exported in 7500 software (Applied Biosystems for 7500 and 7500 Fast Real-Time PCR Products, version 2.0.5). The relative amounts of mRNA were determined based on $2^{-\Delta\Delta Ct}$ calculations with $\beta$-actin as the endogenous reference.

Western Blot analysis to detect the protein expression in vivo and in vitro

Total protein was extracted from the GES-1 cells and tissue samples by ice-cold radioimmunoprecipitation assay (RIPA) buffer supplemented with phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail, and protease inhibitor. Protein concentration was detected by using a bicinchoninic acid assay (BCA) protein assay kit (Solarbio, Beijing, China). The polyvinylidene difluoride (PVDF) membranes were incubated with the primary antibodies at 4°C overnight, including rabbit anti-JMJD2B monoclonal antibody (ab191434, Abcam, dilution: 1:1,000), rabbit anti-COX-2 antibody (12375-1-AP, Proteintech, dilution: 1:500), rabbit anti-VEGFR1 antibody (ab32152, Abcam, dilution: 1:2,500), rabbit anti-VEGFR2 antibody (ab221679, Abcam, dilution: 1:1,000), and anti-beta actin antibody (bs-0061R, Bioss, dilution: 1: 10,000). Then, membranes were washed three times for 5 min each with TBS-0.1% Tween 20 (TBST) and incubated with HRP-conjugated secondary antibody (goat anti-rabbit IgG (H + L) (Zhongshan Golden Bridge Biotechnology; dilution, 1:25000; ZB-2301) for 1 h at room temperature. The antigen-antibody bands were detected by using the solution and visualized by using the X-ray film (Beyotime Institute of Biotechnology). $\beta$-actin was served as an internal control.
Statistical Analysis

All results were presented as mean ± standard deviation (SD) and analyzed with the SPSS software program (version 19.0; SPSS Inc., Chicago, IL, USA). The differences were considered to be statistically significant when $P < 0.05$ and highly significant when $P < 0.01$.

Results

Macroscopic pathology

Firstly, after 8 weeks, the rapid urease test in the model group was positive (Fig.1A). After 4-week ZJP administration, the result of rapid urease test in low dose group was negative (Fig.1B). During 8-week *H. pylori* infection, the rats induced by *H. pylori* exhibited CAG symptoms, such as weight loss, diarrhea and loss of appetite (Fig.1C). The gastric mucosa of rats in model group showed paleness and thinning of gastric mucosa, with disarrayed plicae and small white nodules (Fig.1D).

Histological examination of gastric mucosa

Histological features were critical evidence for the therapeutic effects of ZJP against *H. pylori*-induced CAG. Rats in the control group showed mucosal intact with tightly, abundant and orderly gastric glands. CAG model rats showed inherent glands was missing, part of the mucosa was stripped, and neutrophils were infiltrated in the mucosa. Conversely, pathological changes in the omeprazole and the ZJP groups showed significantly improved in terms of the degree of edema, hyperemia, erosion and atrophy of gastric mucosa. Administration of high dose ZJP particularly exhibited lower inflammatory cell infiltration and gastric mucosal injury. Results were presented in Fig.1E.

Cell viability

CCK8 was used for determination of the optimal concentration for ZJP administration. (Fig.2A). The results showed that ZJP treatment for 24 h potently suppressed cell viability in a concentration-dependent manner with the increasing concentration (0, 10, 20, 30, 40, 60 and 120 $\mu$g/ml). The results showed that 120 $\mu$g/ml of ZJP could significantly inhibit the cell viability ($P < 0.01$). When 60 $\mu$g/mL of ZJP was given, the cell viability was close to 100%. Accordingly, 60 $\mu$g/mL of ZJP played a relatively protective role and was used as the optimal concentration to investigate the protective effects. For the *in vitro* study, 30 and 60 $\mu$g/mL of ZJP were used as low-dose and high-dose to GES-1 cells, respectively.

Expression of JMID2B in GES-1 cells with *H. pylori* infection

It has been reported that the expression of JMJD2B increased with *H. pylori* infection. GES-1 cells were infected with *H. pylori* at different MOI (10:1, 20:1, 50:1, 100:1) through 24 h. As expected, *H. pylori* infection at a lower MOI (10:1, 20:1, 50:1) resulted in a dose-dependent induction (Fig.2B). When MOI=100:1, there were a number of cells floating in the culture medium. Thus, MOI=50:1 was chosen for
further study. By co-culture of *H. pylori* and GES-1 cells for 0, 6, 12, 24 h, the mRNA expression of JMJD2B increased in a time-dependent manner, but there was no significant difference between 12 h and 24 h (MOI=50:1) (Fig.2C). Therefore, MOI=50:1 infection was finally chosen for 12 h for further research.

**High-Content Analysis Experiments**

In order to further determine the influence of ZJP on cell morphology, HCS was used to investigate the effect of ZJP on the morphology of GES-1 cells. Nucleus staining (blue fluorescence), cell cytoplasm labeling (green fluorescence), and dead cells (red fluorescence) were marked by Hoechst 33342, calcein AM, and EthD-1, respectively (Fig. 3A). In the control group, nucleus and cytoplasm of GES-1 cells possessed a homogenous Hoechst and calcein AM fluorescence. After infection of *H. pylori*, there were cell viability, cell number and morphological changes, such as nuclear deformations, cell count decreased, green and red fluorescence reduced and increased, respectively. ZJP could certainly boost the green fluorescence and reduce the red fluorescence of GES-1 cells (Fig.3B-D). These results indicated that ZJP could ameliorate nuclear morphology and cell proliferation in *H. pylori*-induced injury.

**JMJD2B/COX-2/VEGF axis mRNA and protein expression *in Vivo***

Previous gene ontology analysis revealed that JMJD2B regulates VEGF signaling pathways and angiogenesis which play important roles in inflammation or cancer progression [14]. Blood circulation disorders significantly influence pathological process of CAG. VEGF is the target gene to closely regulate angiogenesis, which can stimulate the proliferation of epithelial cells, the formation of blood capillaries, and then participating in the defense and repair of gastric mucosa. Widely accepted, COX-2 is a prostaglandin-endoperoxide synthase, which is responsible for the formation of thromboxanes as a key rate-limiting enzyme. In *H. pylori*-infected gastric mucosal cells, COX-2 is involved in the regulation of VEGF expression [20]. Nevertheless, whether ZJP could interfere with CAG through JMJD2B/COX-2/VEGF axis has not been studied. IHC revealed that Control group samples expressed low levels of JMJD2B as evidenced by barely positive staining of JMJD2B in gastric mucosal cells. Correspondingly, model group samples hold higher level of COX-2 compared with non-infected tissues. Interfered by ZJP, the expression of JMJD2B and COX-2 decreased (Fig.4).

Compared with control group, the serum TNF-α level was significantly increased in model group. After administration of ZJP group (0.63, 1.26 and 2.52 g/kg), TNF-α significantly reduced, and the high dose group (2.52 g/kg g) and Omeprazole group had lower level of TNF-α compared with group with low dose group and medium dose group (Fig. 5F).Moreover, RT-qPCR and Western Blot were used to explore intervention effect of ZJP on JMJD2B/COX-2/VEGF axis (Fig.5B-K). Compared with control group, JMJD2B, COX-2, VEGF, VEGFR1 and VEGFR2 expressed at a relatively high level in model group. However, the mRNA and protein expression levels of these genes in the ZJP groups were decreased. High dose
group of ZJP could significantly reduce the mRNA and protein expression levels, while, the medium and low dose group of ZJP exhibited weaker reduction.

**JMJD2B/COX-2/VEGF axis mRNA and protein expression in vitro**

We previously demonstrated that the mRNA and protein levels of JMJD2B, COX-2, VEGF, VEGFR1 and VEGFR2 were significantly decreased following intervention of ZJP. In order to further explore the effect of ZJP on JMJD2B/COX-2/VEGF axis, the model of *H. pylori* induced (MOI=50:1, 12h) GES-1 cells was established (Fig.6). The IL-8 mRNA level was significantly increased in *H. pylori*-infected cells. ZJP at 30 μg/mL and 60 μg/mL could all decrease the IL-8 mRNA level compared to control group (Fig.6G). Evidently, the expression of JMJD2B, COX-2, VEGF, VEGFR1 and VEGFR2 were increased in *H. pylori*-infected cells compared with the control group.

Administration of ZJP at high dose (60 μg/mL) expressed lower level of JMJD2B and its downstream genes noticeably compared with the *H. pylori*-infected group and low dose (30 μg/mL) group. The results further emphasize that ZJP may relieve *H. pylori*-induced inflammation and gastric mucosa injury via the downregulation of JMJD2B/COX-2/VEGF axis.

**Discussion**

In this study, results revealed that ZJP could suppress the JMJD2B/COX-2/VEGF axis to exhibit anti-inflammatory properties in *H. pylori*-induced CAG. It could attenuate the gastric mucosal injury by suppressing the inflammatory factor via inhibiting COX-2 and VEGF expression, which is involved in the anti-inflammatory effect of ZJP in CAG with *H. pylori* induction. Our study set the foundation to explore the mechanism and pharmacological effects of ZJP in the treatment of *H. pylori*-induced CAG.

*H. pylori* is a Gram-negative bacterium and colonizes approximately over 50% of the world’s population, with a variable prevalence in different regions. *H. pylori* was classified as a class I carcinogenic factor by the International Agency for Research on Cancer in 1994. *H. pylori* is a major human pathogen causing progressive, chronic gastric mucosal injury and linked to CAG and gastric cancer. Epigenetics plays the vital role in the development and progression of gastric cancer [21]. *H. pylori* infection induces epigenetic changes, like DNA methylation and histone modification, which play important roles in oncogenic transformation [22]. Histone modification, an epigenetic mechanism, which plays a crucial role in GC carcinogenesis [23]. The family of JMJD2 consists of JMJD2A, JMJD2B, and JMJD2C. JMJD2B specifically catalyzes the removal of di- and trimethylated H3K9 (H3K9me2/me3), converting both histone marks to the monomethylated state [24]. Thus, JMJD2B plays a role as a transcriptional activator [24]. Previous studies have discovered that *H. pylori* infection can affect JMJD2B expression in gastric epithelial cells, which is involved in the pathological development of gastric cancer [25]. As we all know, COX, as a key rate-limiting enzyme, promotes arachidonic acid convert to prostanoids and thromboxanes,
which has two forms, COX-1 and COX-2. COX-1 maintains normal function in most tissues. In contrast, COX-2 associated with pain, inflammatory reaction, tumorigenesis and so on. Besides, the expression of COX-2 is known to be increased in the gastric mucosa of *H. pylori*-infected gastritis patients [26]. In *H. pylori*-infected gastritis, there is an increase in angiogenic factors, and subsequently a formation of new blood vessels. New angiogenesis will enhance supply of nutrient and oxygen, and promote the development of gastritis [27]. Gastritis induced by *H. pylori* is related to VEGF, and the overexpression of VEGF is parallel to the increase in gastric mucosal vascularization [28]. VEGF is the key regulator of inflammation-related angiogenesis and overexpression in gastric diseases induced by *H. pylori* [29]. On the one hand, VEGF involved in the construction of normal mucosal. On the other hand, it also accelerates gastric carcinomas by supporting tumor-associated angiogenesis [30]. COX-2 induced the overexpression of VEGF in gastric tissues colonized by *H. pylori* [33]. *H. pylori* infection might be able to induce the expression of COX-2 in gastric tissue, which in turn upregulates the expression of VEGF [31]. In this present study, we verified the role of the JMJD2B/COX-2/VEGF axis in *H. pylori* induced CAG.

In this current study, the effect of JMJD2B/COX-2/VEGF axis is verified one more time *in vitro* and *in vivo*. The role of the axis in the promotion of gastric mucosa damage and inflammatory responses has been described. Consequently, it is potential that activation of JMJD2B/COX-2/VEGF axis may accelerate the process of chronic infection or even has high tendency of canceration. In this study, the expression of proinflammatory genes, including JMJD2B, COX-2, VEGF, VEGFR1, VEGFR2, and TNF-a were probed in SD rats when *H. pylori* infection. We found that the expression of TNF-a was activated in *H. pylori* induced rats. In addition, genes in JMJD2B/COX-2/VEGF axis also increased after *H. pylori* infection. Next, the genes related to JMJD2B/COX-2/VEGF axis were quested in the *H. pylori*-infected cells. Accordingly, the expression of JMJD2B, COX-2 and downstream genes including VEGF, VEGFR1 and VEGFR2 were increased significantly in *H. pylori*-infected cells. We also revealed the protein expression in JMJD2B/COX-2/VEGF axis got escalated in *H. pylori*-infected GES-1 cells and gastric mucosa. There is no denying that JMJD2B/COX-2/VEGF axis exerts pivotal effects in chronic inflammation process induced by *H. pylori*.

In China, Chinese medicine and prescriptions based on the theories of TCM have been considered. TCM, as a complementary therapy, has achieved vital effects in treating CAG and broadened the ideas of therapeutic approaches for CAG [32]. ZJP has been used for the treatment of gastrointestinal disorders in the clinical practice of TCM more than 600 years. According to the current official Chinese Pharmacopoeia, ZJP has been prescribed as the effective prescription of gastritis, pyloric obstruction, gastric ulcer, gastroesophageal reflux disease, etc. In this study, we explored the pharmacological effects of ZJP in the treatment of *H. pylori*-induced CAG. The mechanism of ZJP in treating *H. pylori*-infected CAG were also explored by analyzing the JMJD2B/COX-2/VEGF axis. In our examination, we found that ZJP administration significantly improved the cell protection from *H. pylori* infection. Cell viability, morphological identification of GES-1 cells was directly ameliorated following ZJP administration. The pathological changes of gastric mucosa, including arrangement of gastric glands, infiltration of lymphocytes and plasma cells, were also better than model group. The specific marker of serum TNF-a significantly decreased after intervened by ZJP. We speculated that with *H. pylori* activity intervened by
ZJP, the inflammation level and damage of gastric mucosa returned to normal levels. In terms of mechanism of ZJP in treating *H. pylori*-infected CAG, the proinflammatory genes, encoding JMJD2B, IL-8, COX-2, VEGF and its downstream genes were either significantly downregulated by ZJP intervention in GES-1 cells. These results support the role of ZJP as an anti-inflammatory agent in GES-1 cells damage induced by *H. pylori*. We also demonstrated the expression of JMJD2B/COX-2/VEGF axis including JMJD2B, COX-2, VEGF, VEGFR1 and VEGFR2 were significantly suppressed in *H. pylori*-infected gastric mucosa. Meanwhile, we revealed the protein expression in JMJD2B/COX-2/VEGF axis was downregulated after exposure to ZJP. Taken together, these results suggested that ZJP which could block the course of JMJD2B/COX-2/VEGF axis to *H. pylori*-infected procession *in vivo* and *in vitro*.

**Conclusions**

Taken together, our study confirmed the therapeutic effect of ZJP in *H. pylori*-induced CAG model. We also found that Histone demethylase played a vital role in CAG model. Importantly, ZJP prevented gastric mucosal injury by inhibiting the *H. pylori*-mediated inflammation via JMJD2B/COX-2/VEGF axis. The results from this study suggest a potential role of ZJP in treatment of CAG, which need to be further investigated.

**Declarations**

**Acknowledgements**

Not applicable.

**Authors’ contributions**

Design of the study: Shihua Wu, Ruilin Wang, Chunmei Bao, Xiaomei Zhang and Jianzhong Zhang; data collection and analysis: Sijia Gao, Weihan Qin, Juling Zhang, Ruisheng Li, Xing Chen, Jiaxia Wen and Tao Yang; drafting the manuscript: Shizhang Wei, Haotian Li, Ying Wei, Sichen Ren; supervising and providing Funding acquisition: Yanling Zhao, HouLin Xia. All authors participated in amending the manuscript before submission of the mutually agreed final version.

**Funding**

This study was supported by the National key R & D Program of China [No. 2018YFC1704500].

**Availability of data and materials**

The datasets used and/or analyzed in the present study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate

The experimental protocols were approved by the Ethics Committee of the Ethics of Animal Experiments of the Fifth Medical Center of PLA General Hospital (Approval ID: IACUC-2018-010).

Consent for publication

All authors agree to publish this paper.

Competing interests

The authors declare that they have no competing interests.

Author details

1 College of pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. 2 Department of Pharmacy, The Fifth Medical Center of PLA General Hospital, Beijing, China. 3 Division of Clinical Microbiology, The Fifth Medical Center of PLA General Hospital, Beijing, China. 4 Integrative Medical Center, The Fifth Medical Center of PLA General Hospital, Beijing, China. 5 Institute of Medicinal Chemistry of Chinese Medicine, Chongqing Academy of Chinese Materia Medica, Chongqing, China. 6 Center of Disease Control and Prevention, National Institute for Communicable Disease Control and Prevention, Beijing, China. 7 Research Center for Clinical and Translational Medicine, The Fifth Medical Center of PLA General Hospital, Beijing, China. 8 College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Abbreviations

ZJP: Zuojin Pill; CAG: Chronic atrophic gastritis; Helicobacter pylori. H. pylori, COX-2: Cyclooxygenase-2; VEGF: Vascular endothelial growth factor; TCM: Traditional Chinese medicine; CR: Coptidis Rhizoma; EF: Euodiae Fructus; DMSO: Dimethyl sulfoxide; DMEM: Dulbecco's modified Eagle's medium; CFU: Colony forming units; SD: Sprague-Dawley; SPF: Specific pathogen free; H&E: Hematoxylin and eosin; CCK-8: Cell counting kit-8; OD: Optical density; MOI: Multiplicity of infection; HCS: High-Content Analysis Experiments; IHC: Immunohistochemical staining.

References

[1] Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354-362.

[2] Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2-9.
[3] Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z, et al. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clin Microbiol Infect. 2017; 23(6):391-395.

[4] Wang YC. Medicinal plant activity on Helicobacter pylori related diseases. World J Gastroenterol. 2014; 20(30):10368-82.

[5] Wang J, Wang L, Lou GH, Zeng HR, Hu J, Huang QW, et al. Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharm Biol. 2019;57(1):193-225.

[6] Xu S, Peng J, Li Y, He L, Chen F, Zhang J, et al. Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats. J Ethnopharmacol. 2012;139(2):395-400.

[7] Wang J, Zhang T, Zhu L, Ma C, Wang S. Anti-ulcerogenic effect of Zuojin Pill against ethanol-induced acute gastric lesion in animal models. J Ethnopharmacol. 2015;173:459-67.

[8] Wang QS, Zhu XN, Jiang HL, Wang GF, Cui YL. Protective effects of alginate-chitosan microspheres loaded with alkaloids from Coptis chinensis Franch. and Evodia rutaecarpa (Juss.) Benth. (Zuojin Pill) against ethanol-induced acute gastric mucosal injury in rats. Drug Des Devel Ther. 2015;9:6151-65.

[9] Yang T, Wang R, Zhang J, Bao C, Zhang J, Li R, et al. Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-γ signaling axis suppressing. Life Sci. 2020 May 1;248:117456

[10] Wang T, Yan YF, Yang L, Huang YZ, Duan XH, Su KH, et al. Effects of Zuojin pill on depressive behavior and gastrointestinal function in rats with chronic unpredictable mild stress: Role of the brain-gut axis. J Ethnopharmacol. 2020;254:112713.

[11] Han F, Ren J, Zhang J, Sun Y, Ma F, Liu Z, et al. JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression. Oncotarget. 2016;7(25):38626-38637.

[12] Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z. Expression profiles of histone modification genes in gastric cancer progression orkmaz. Clin Microbiol Infect. 2017;23(6):391-395.

[13] Zhao L, Li W, Zang W, Liu Z, Xu X, Yu H, et al. JMJD2B promotes epithelial-mesenchymal transition by cooperating with beta-catenin and enhances gastric cancer metastasis. Clin Cancer Res. 2013;19(23):6419-29.

[14] Liu D, He Q, Liu C. Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia. J Gastroenterol Hepatol. 2010;25(4):795-9.
[15] Sierra JC, Hobbs S, Chaturvedi R, Yan F, Wilson KT, Peek RM Jr, et al. Induction of COX-2 expression by Helicobacter pylori is mediated by activation of epidermal growth factor receptor in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2013;305(2):G196-203.

[16] Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010;70(16):6456-66.

[17] Liu N, Zhou N, Chai N, Liu X, Jiang H, Wu Q, et al. Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer. BMC Cancer. 2016;16:321.

[18] Wen J, Zhang L, Liu H, Wang J, Li J, Yang Y, et al. Salsolinol Attenuates Doxorubicin-Induced Chronic Heart Failure in Rats and Improves Mitochondrial Function in H9c2 Cardiomyocytes. Front Pharmacol. 2019;10:1135.

[19] Chen M, Tung CW, Shi Q, Guo L, Shi L, Fang H, et al. A testing strategy to predict risk of drug-induced liver injury in humans using high-content assays and the “rule-of-two” model. Arch Toxicol. 2014;88(7):1439-49.

[20] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2015;65(2):87-108.

[21] Chen P, Guo H, Wu X, Li J, Duan X, Ba Q, et al. Epigenetic silencing of microRNA-204 by Helicobacter pylori augments the NF-κB signaling pathway in gastric cancer development and progression. Carcinogenesis. 2019. pii: bgz143.

[22] Ding SZ, Goldberg JB, Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol. 2010;6(5):851-862.

[23] Shi L, Sun L, Li Q, et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A. 2011;108(18):7541-7546.

[24] Whetstine JR, Nottke A, Lan F, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006;125(3):467-481.

[25] Zhang J, Ren J, Hao S, Ma F, Xin Y, Jia W, et al. MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer. Am J Transl Res. 2018;10(2):525-534.

[26] Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 1999;116(6):1319-1329.
[27] Tian G, Wu C, Li J, et al. Network pharmacology based investigation into the effect and mechanism of Modified Sijunzi Decoction against the subtypes of chronic atrophic gastritis. Pharmacol Res. 2019;144:158-166.

[28] Tuccillo C, Cuomo A, Rocco A, Martinelli E, Staibano S, Mascolo M, et al. Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. J Pathol. 2005;207(3):277-84.

[29] Strowski MZ, Cramer T, Schäfer G, et al. Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J. 2004;18(1):218-220.

[30] Basu S, Pathak SK, Chatterjee G, Pathak S, Basu J, Kundu M. Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. J Biol Chem. 2008;283(47):32369-32376.

[31] Caputo R, Tuccillo C, Manzo BA, et al. Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. Clin Cancer Res. 2003;9(6):2015-2021.

Table

Table 1 Primers used for real-time PCR

|         | Primers | Sequence-Forward       | Sequence-Reverse       |
|---------|---------|------------------------|------------------------|
| **Cells** |         |                        |                        |
| JMJ2B   | CCTTCCTGCAGCATAAGATGAC | GGTGGCGGAAGTTGATTTCTG  |
| COX-2   | AATCTGGGCGGGAACACTCA   | TGGCTGGAACACTGCTACCCA  |
| VEGF    | GCTTGGCTTGTGGCTCTTACC  | CTTCGTGATTTCTGCGCTCCTC |
| VEGFR1  | TGGTGATGAAGAAACACTG    | GTGTGTGTGTGTGTGTGGTTC  |
| VEGFR2  | AGGGAGCTCTGTCGATCGAAGG | GTGGTGATCTGTCATCGGAGTG |
| IL-8    | GCTCTGTGTGAGGAGGTG    | TTCTGGGTTGGCTAGAGTGT   |
| β-actin | GGCACCACACCTTCTACAGTAC | GATAGCACACCCCTTGATAGCAAC |
| **Rats** |         |                        |                        |
| JMJ2B   | CTACTACCCTGCCCTGCTCTT  | CTCTGGCTTTGTGGCTCTCTTGATAC |
| COX-2   | CAGTACGCAGTAGAGTGATTC  | CAGGGCACCACACCCCTTGATAGCAAC |
| VEGF    | CAGCAACAGGAGGAGCAGAAAG | GGCaCAGAAGGCAGCAGCAGAGT |
| VEGFR1  | GAGCATCTATCAGGACGGGATTG | CGACCACCTCTCCACAGAGAC |
| VEGFR2  | TGCCAAATCCCGTCCTCAAGC  | CTTGGGCTACTCCTGTCACACTG |
| β-actin | CCCGGCAGTACCCCTCTTGG   | TCATCCATGGCGAATCTGCT   |

Figures
Figure 1

Macro performance of CAG in rats. (A) Rapid urease test of stomach tissues. (B) Rapid urease test of stomach tissues. (C) Weight of rats. (D) Morphology of gastric mucosa stomach tissue (n=3). (F) H & E staining of chronic atrophic gastritis in rats (×200, ×400). Data were shown as mean ± SD;
Figure 2

Cell activity and model determination. (A) Effect of ZJP on cell viability (10μg/mL-120μg/mL). (B) JMJD2B mRNA expression in different MOI of H. pylori (MOI=10:1, 20:1, 50:1 and 100:1). (C) JMJD2B mRNA expression in different infection time of H. pylori. (T=0, 6, 12 and 24 hours). ##P < 0.01 versus control group, #P < 0.05 versus control group. Data were shown as mean ± SD (n=3).
**Figure 3**

High-Content Analysis Experiments in GES-1 cells. (A) Green fluorescence, red fluorescence and blue fluorescence reflect living cells, dead cells and nuclei respectively. Scale bar=50 μm. (B) Valid cell counts of HCS analysis for GES-1 cells (% of control). (C) Living cell counts of GES-1 cells (MEAN_TargetAvgIntenCh2). (D) Dead cell counts of GES-1 cells (MEAN_TargetAvgIntenCh3). ##P < 0.01 versus control group. #P < 0.05 versus control group. **P < 0.01 versus H. pylori infection group. The
results are expressed as percentages of control group. Data were shown as mean ± SD. Control, control group; ZJP, Zuojin Pill. H. pylori, Helicobacter pylori (n=3).

Figure 4

Effect of ZJP at different doses on JMJD2B and COX-2 expression in rats with H. pylori-induced CAG. (A) Expression of JMJD2B in different groups. (B) Expression of COX-2 in different groups.
Figure 5

Effects of ZJP on the JMJD2B/COX-2/VEGF axis mRNA and protein expression in vivo with H. pylori infection. (A-E) The mRNA expression of JMJD2B/COX-2/VEGF axis. (F) The expression level of TNF-a in rat serum. (G-K) The protein expression of JMJD2B/COX-2/VEGF axis. All data are presented as mean ± SD. ###P < 0.01 versus control group; *P < 0.05 versus model group; **P < 0.01 versus model group (n=3).
Figure 6

Effects of ZJP on the JMJD2B/COX-2/VEGF axis mRNA and protein expression in vitro with H. pylori infection. (A-E) The mRNA expression of JMJD2B/COX-2/VEGF axis. (F) IL-8 mRNA expression in GES-1 cells. (G-J) The protein expression of JMJD2B, COX-2 and VEGFR2. All data are presented as mean ± SD. 
##P < 0.01 versus control group;∗P < 0.05 versus model group;∗∗P < 0.01 versus model group(n=3).
Figure 7

Effect of ZJP at different doses on JMJD2B and COX-2 expression in rats with H. pylori-induced CAG. (A) Expression of JMJD2B in different groups. (B) Expression of COX-2 in different groups.
Figure 8

Effects of ZJP on the JMJD2B/COX-2/VEGF axis mRNA and protein expression in vivo with H. pylori infection. (A-E) The mRNA expression of JMJD2B/COX-2/VEGF axis. (F-G) The protein expression of JMJD2B/COX-2/VEGF axis. All data are presented as mean ± SD and analyzed by one-way ANOVA followed by t-test. ##P < 0.01 versus control group; *P < 0.05 versus model group; **P < 0.01 versus model group (n=3).
Figure 9

Effects of ZJP on the JMJD2B/COX-2/VEGF axis mRNA and protein expression in vitro with H. pylori infection. (A-E) The mRNA expression of JMJD2B/COX-2/VEGF axis. (F) The protein expression of JMJD2B, COX-2 and VEGFR2. All data are presented as mean ± SD and analyzed by one-way ANOVA followed by t-test. ##P < 0.01 versus control group; *P < 0.05 versus model group; **P < 0.01 versus model group (n=3).